There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Verve Therapeutics (VERV – Research Report), Immunovant (IMVT – Research Report) and TELA Bio (TELA – Research Report) with bullish sentiments.
Verve Therapeutics (VERV)
In a report released today, Whitney Ijem from Canaccord Genuity maintained a Buy rating on Verve Therapeutics, with a price target of $29.00. The company’s shares closed last Monday at $9.17, close to its 52-week low of $8.52.
According to TipRanks.com, Ijem is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Verve Therapeutics with a $37.00 average price target, representing a 280.7% upside. In a report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $55.00 price target.
See today’s best-performing stocks on TipRanks >>
Immunovant (IMVT)
Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Immunovant today and set a price target of $57.00. The company’s shares closed last Monday at $33.80.
According to TipRanks.com, Rahimi is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Immunovant with a $44.92 average price target, a 32.6% upside from current levels. In a report issued on October 13, UBS also upgraded the stock to Buy with a $55.00 price target.
TELA Bio (TELA)
In a report released yesterday, Caitlin Cronin from Canaccord Genuity maintained a Buy rating on TELA Bio, with a price target of $15.00. The company’s shares closed last Monday at $5.66, close to its 52-week low of $5.59.
Currently, the analyst consensus on TELA Bio is a Strong Buy with an average price target of $17.00, implying a 196.2% upside from current levels. In a report released yesterday, Lake Street also reiterated a Buy rating on the stock with a $18.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VERV:
- Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia
- William Blair biotech analyst to hold an analyst/industry conference call
- Verve Therapeutics to present Phase 1b data on HeFH candidate
- Verve to Present Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in HeFH Patients at the American Heart Association’s Scientific Sessions 2023
- Verve Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
